The NeuraMetrix solution provides Biopharmaceutical companies with a much more precise, accurate, and cost-effective Digital Cognitive Biomarker for Clinical Drug Development
pharmaceutical sales rep meeting with a pharma companypharmaceutical sales rep meeting with a pharma company

The gap

The main issues for drug trials within neurological diseases and psychiatric disorders today are
  • Do not have good and early indicators of safety and efficacy
  • Difficult to successfully develop new drugs when the cohort is based on patients where the disease has already progressed beyond where the drugs can have an impact
  • No ability to monitor "in real-time" the effect on each trial participant
  • Difficult to measure cognitive side effects of their drugs

NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry

With the NeuraMetrix digital biomarker drug trials for neurological diseases and psychiatric disorders can:
  • Have earlier, more sensitive and less variable indicators of safety and efficacy
  • Get objective sensitive measures of disease state, disease progression and response to therapy in clinic and at home
  • Identify patient segmentation strategies
  • Granular quantification of disease symptoms
  • Detect known drug effect by monitoring drug compliance
This enables biotech and pharmaceutical companies to: 
  • Smaller, shorter duration of clinical trials
  • Make it easier for the cohort
  • Increase prognostic enrichment: selection of patients at high risk of disease-related endpoints
  • Increase predictive enrichment: selection of patients sub segment with disease stages more likely to drug treatment 
  • Narrow the range of scores for inclusion into a trial
  • Have trials designs which include pre-randomization baseline "run-in" period to exclude patients whose symptoms resolve spontameously or have highly variable baseline symptoms
  • Identify patients likely to adhere to treatment
  • Identify responders vs. non-responders by quantifying patient symptoms and track longitudinally  
Resulting in:
  • Faster go/no go decisions
  • Decreased variability
  • Decreased heterogeneity
  • Increased study power
  • Better management of drug trials
  • Fewer participants dropping out of drug trials 
  • Less risk
  • Less cost